Pleasanton, Calif.-based biotechnology startup 10x Genomics went public on Sept. 12, opening on the Nasdaq Stock Market at a price of $39 per share.
The company's initial public offering price was several times higher than previously expected: A prospectus filed with the SEC in August proposed an IPO of $100 million. At $39 per share, however, and with 10 million shares in the offering, 10x Genomics' actual IPO could amount up to $390 million.
Upon its stock market debut, the company, trading under the symbol TXG, opened at $54 per share and peaked at $58 per share. According to Barron's, this performance places 10x Genomics' valuation around $5.2 billon, well above the $1.28 billion figure estimated by Forbes earlier this year.
More articles on health IT:
Email wire fraud has cost $26B in losses in 3 years, FBI finds: 4 things to know
UnitedHealthcare accelerator chooses 10 digital health startups for inaugural cohort
GE Healthcare's AI X-ray device 1st to receive FDA clearance